CAD-IT Australia supports the life science community and is driven by a clear goal: to redefine possibilities. Our expertise lies in tailor-made digital solutions, carefully crafted to tackle the specific challenges of the sector.
Cytiva are a global provider of technologies and services that advances and accelerates the development, manufacture, and delivery of therapeutics. We’re bringing together a wealth of technical expertise and talent, broad and deep portfolio, and exceptional service to help researchers and biopharma advance therapeutics at every stage: from discovery to delivery.
IQVIA is a global leader in clinical research, healthcare intelligence, and commercial insights for the life sciences sector. The company supports innovation and improved patient outcomes. With around 88,000 employees across 100+ countries, IQVIA helps accelerate the development and delivery of medical treatments.
QIMR Berghofer is one of Australia’s largest medical research institutes, renowned for its world-leading research in cancer, infection and inflammation, brain and mental health, and population health. QIMR Berghofer is home to almost 1,000 scientists, students and support staff in more than 60 state-of-the-art laboratories.
The Translational Research Institute (TRI) is an Australian initiative focused on advancing medical research from the laboratory to the community. Combining clinical and translational research, TRI aims to enhance detection, diagnosis, and treatment methods for various health conditions, ultimately improving patient outcomes. Their work spans across different areas, including cancer, autoimmune diseases, and more, with a focus on developing innovative treatments and diagnostics that can be translated into better healthcare practices.
Vaxxas is commercialising novel technology that dramatically enhances the performance of existing next-generational vaccines. Their delivery platform enables robust immune system activation by targeting vaccine components to the abundant immunological cells immediately below the skin’s surface. Vaxxas’ proprietary Nanopatch™ technology aims to provide an optimised, differentiated needle-free vaccine delivery solution that safely and cost effectively amplifies vaccine efficacy.
